News | Bertelsmann Investments | Gütersloh, 05/21/2025

Bertelsmann Investments Further Expands Pharma Tech Unit by Acquiring Docuvera

• Acquisition made as part of the Bertelsmann Next growth program
• Pharma Tech unit cormeo now comprises Docuvera, EXTEDO and Rote Liste
• Further investments envisaged in the pharma tech space going forward

Gütersloh, May 21, 2025 – Bertelsmann Investments – through its Pharma Tech unit cormeo – acquires a 100 percent in Docuvera, a pioneer in AI-driven structured content authoring for the life sciences industry. The acquisition is part of the Bertelsmann Next program which encompasses growth initiatives in Pharma Tech (cormeo), HR Tech (EMBRACE) and Mobile Ad Tech (Applike).

Docuvera will join the existing cormeo businesses EXTEDO and Rote Liste, enriching the company’s offering of complementary tools for the life sciences sector. The acquisition marks the next milestone for cormeo on the journey to build an end-to-end solution suite for life sciences information lifecycle management.

Deniz Pielsticker, CFO of Bertelsmann Investments, said: "The acquisition of Docuvera complements our Pharma Tech unit cormeo and is a testament to Bertelsmann Investment’s continued commitment to the Pharma Tech space. As part of the Bertelsmann Next growth program, we will continue to invest behind the cormeo team – which is led by CEO Peter Koop – both organically and through acquisitions.”

Peter Koop, CEO of cormeo, said: “We are excited to welcome Docuvera into the cormeo family. This acquisition not only further strengthens our portfolio but also accelerates our vision of delivering cutting-edge solutions that meet the evolving needs of the life sciences sector.”

Tobias Beer, COO of cormeo and Member of the Advisory Board at Docuvera, said: “Acquiring Docuvera is a pivotal step in our journey towards realizing a seamless end-to-end information lifecycle. With Docuvera’s strengths in structured content authoring and AI, we can empower our clients to streamline content operations, enhance efficiency, and reduce compliance risk through greater consistency and traceability of regulated content.”

With its advanced AI and structured content authoring capabilities, Docuvera empowers life sciences organizations to streamline operations, reduce time to market, and mitigate compliance risks. The acquisition positions cormeo to further enhance its portfolio of innovative brands and strengthen its role as a comprehensive provider of next-generation content solutions.

Stephen Owens, newly appointed CEO of Docuvera, said: "We are thrilled to fully join the cormeo portfolio. Together, we will continue to push the boundaries of what is possible in life sciences content management, providing solutions for customers to thrive in an increasingly digital world."

About Bertelsmann Investments
Bertelsmann Investments (BI) comprises Bertelsmann’s global venture capital activities as well as the Bertelsmann Next growth unit. The venture capital arm includes the funds Bertelsmann Asia Investments (BAI), Bertelsmann India Investments (BII) and Bertelsmann Digital Media Investments (BDMI), as well as selected fund and direct holdings in markets including Europe, the United States, Brazil, Southeast Asia, and Africa. The Bertelsmann Next unit advances the entrepreneurial development of new growth sectors and business areas, including HR Tech, mobile ad tech and Pharma Tech. To date, around €1.9 billion has been invested in about 500 innovative companies and funds through Bertelsmann Investments. Bertelsmann Investments currently holds over 370 active investments worldwide through its network of start-ups and funds.

About cormeo
cormeo unites the expertise of Docuvera, EXTEDO, and Rote Liste to provide a seamless end-to-end approach to creating, managing, and distributing regulated information in the life sciences sector. Together, we build the trusted bridge between industry, authorities, healthcare professionals, and patients, facilitating the innovative and compliant exchange of regulated information in life sciences to improve patient health.
At the core of information creation, Docuvera transforms content creation, review, approval, and translation by providing a solution for AI-powered structured content authoring. In the sphere of information management, EXTEDO provides regulatory information and quality management solutions to industry and authorities that support the entire lifecycle of medicinal products. For information distribution, Rote Liste plays a vital role in distributing medical information to healthcare professionals and patients, empowering them to make informed decisions with confidence.
cormeo is shaping the future of life science information management. With our strong commitment to digital transformation, compliance, and patient health, we empower the life sciences industry to enhance efficiency and innovation. For more information, visit https://www.cormeo.com  .

About Docuvera
Docuvera Software Corporation (Docuvera) is a globally recognized leader in structured content authoring solutions for the pharmaceutical and life sciences industries. Headquartered in New Zealand, Docuvera solutions have been implemented world-wide for more than a decade to strengthen regulatory compliance and governance as well as significantly improve content standardization/reuse efficiency and approval submissions/time to market. The company’s embedding of its proprietary artificial intelligence (AI) into the solution has further fortified the Docuvera value proposition as a sought-after solution for pharmaceutical and life sciences documentation use cases as well as a platform for customers to further digital transformation initiatives. For more information, visit https://docuvera.com  .